Microglia and astrocyte activation pathways

Microglia and astrocyte activation pathways represent the coordinated cellular and molecular responses of the central nervous system's primary glial cells to pathological stimuli (NIH, 2021). These pathways are not a single molecular target but encompass the transition of microglia and astrocytes from homeostatic to reactive states, often triggered by damage-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs) acting on receptors like TLR4 (NIH, 2021; ResearchGate, 2023). A critical feature is the bidirectional crosstalk where microglial-derived cytokines, such as IL-1α, TNF, and C1q, induce neurotoxic "A1" astrocyte phenotypes, while astrocytes can reciprocally modulate microglial activity through factors like TGF-β and ATP (NIH, 2023; ResearchGate, 2024). While initially protective, chronic activation of these pathways is a major driver of neurodegeneration in conditions like Alzheimer's disease, Parkinson's disease, and Multiple Sclerosis (NIH, 2019; NIH, 2021). Therapeutic strategies targeting these pathways aim to suppress neuroinflammation or shift glial cells toward neuroprotective, reparative states using small molecules, biologics, or gene therapies (ResearchGate, 2023; NIH, 2019). Monitoring these pathways often involves biomarkers such as GFAP for astrocytes and Iba1 or TSPO for microglia (ResearchGate, 2023; NIH, 2021).

Other names

Neuroinflammation pathwaysGlial activation pathwaysMicroglia-astrocyte crosstalkReactive gliosis pathwaysNeuroinflammatory signaling cascades

Modulation of neuroinflammatory signaling cascades, including the inhibition of pro-inflammatory cytokine production (e.g., IL-1, TNF) and the promotion of neuroprotective or homeostatic glial phenotypes (NIH, 2021; ResearchGate, 2023).